Johnson & Johnson (NYSE:JNJ) Reaches New 1-Year High – Here’s Why

Johnson & Johnson (NYSE:JNJ – Get Free Report)’s stock price hit a new 52-week high during trading on Monday. The stock traded as high as $289.30 and last traded at $289.4330, with a volume of 33,648 shares. The stock had previously closed at $285.75.

Key Stories Impacting Johnson & Johnson

Investors following JNJ have been watching these stories:

  • Positive Sentiment: J&J agreed to acquire clinical-stage Ollin Biosciences, which is developing treatments for serious eye diseases. The purchase could strengthen its ophthalmology business and add future drug candidates, although clinical-stage assets carry development risk. The latest report puts the agreed deal at $2.2 billion; earlier reports described talks involving up to $3.4 billion. Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
  • Neutral Sentiment: ETFs recorded $72.5 million in net J&J sales on Thursday. Another report said State Street’s health-care ETF sold J&J shares as part of a broader portfolio reduction, so the activity may reflect fund rebalancing rather than a company-specific change in outlook. ETFs Are Net Sellers of Johnson & Johnson
  • Negative Sentiment: Executive Vice President Elizabeth Forminard sold 13,072 shares for about $3.72 million, reducing her reported stake by 43.48%. Insider sales can weigh on sentiment, though a single transaction does not establish a change in the company’s fundamentals. Johnson & Johnson EVP Sells 13,072 Shares

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research note on Monday, August 3rd. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Wells Fargo & Company raised their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Finally, Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Get Our Latest Report on Johnson & Johnson

Johnson & Johnson Price Performance

The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $691.27 billion, a PE ratio of 43.46, a P/E/G ratio of 2.82 and a beta of 0.22. The stock’s 50-day moving average is $266.97 and its 200 day moving average is $249.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the company earned $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently modified their holdings of the business. Outlook Capital Management LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $28,000. Navigoe LLC boosted its position in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after acquiring an additional 55 shares in the last quarter. Matrix Trust Co grew its stake in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $43,000. Finally, Hanseatic Management Services Inc. acquired a new position in Johnson & Johnson during the third quarter worth $52,000. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.